Scarica l'app Stockscreener
5.23
2.79%
-0.15
Dopo l'orario di chiusura:
5.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FHTX Giù?
Forum
Previsione
Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health – Company Announcement - Financial Times
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock? - MSN
Layoff Tracker: Q32, Inventiva, Third Harmonic Cut Staff - BioSpace
Eagle financial services executive buys $3,200 in stock - MSN
CENX’s Stock Woes: Up 59.32% in 6 Months, Up 59.32% in Just 5 Days - The InvestChronicle
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Harmony Gold Mining Co Ltd ADR (HMY) Stock: A Study of the Market Performance - The News Heater
Foghorn Therapeutics Inc (FHTX) Shares Up Despite Recent Market Volatility - The News Heater
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks - Markets Insider
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Yahoo Finance
What is B. Riley's Forecast for FHTX FY2024 Earnings? - MarketBeat
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry - Yahoo Finance
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Upgraded by B. Riley - MarketBeat
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - Yahoo Finance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Coverage Initiated by Analysts at B. Riley - MarketBeat
Why Compass Therapeutics Inc (CMPX) Is Skyrocketing So Far In 2025 - Yahoo Finance
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - Yahoo Finance
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains? - Yahoo Finance
Foghorn Therapeutics Advances Drug Development in Oncology - TipRanks
What is B. Riley’s Estimate for FHTX FY2024 Earnings? - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at B. Riley - Defense World
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Upgraded at B. Riley - Defense World
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Foghorn Therapeutics a new buy at B Riley on tumor fighting technology - Seeking Alpha
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B. Riley Initiates Foghorn Therapeutics at Buy With $10 Price Target -January 30, 2025 at 07:56 am EST - Marketscreener.com
Zevra Therapeutics to Participate at Upcoming Investor Conferences - Yahoo Finance
Why Akero Therapeutics Inc. (AKRO) Surged on Monday - Yahoo Finance
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On MondayHere's Why - Yahoo Finance
Foghorn Therapeutics receives Nasdaq compliance notice - MSN
Foghorn Therapeutics receives Nasdaq compliance notice By Investing.com - Investing.com Australia
Strong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year loss - Yahoo Finance
Foghorn Therapeutics (FHTX) Stock Price, News & Analysis - MarketBeat
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation – Company AnnouncementFT.com - Financial Times
Is Compass Therapeutics, Inc. (CMPX) the Hottest Smid-Cap Stock So Far In 2025? - Yahoo Finance
Barclays PLC Grows Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week - Yahoo Finance
Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials - openPR
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):